文献速递中毒与环境急症复苏、休克与脓毒症重症综合管理与镇静镇痛

叠氮化钠中毒:叙述性综述

Sodium azide poisoning: a narrative review.
PubMed 文献 · Clin Toxicol (Phila) · 2021-06-15
一句话结论综述156例叠氮化钠中毒病例,低血压常见且可需血管加压药,作者基于机制认为羟钴胺是合理选择。

该叙述性综述检索2000年1月1日至2020年12月31日的医学与报纸数据库,纳入描述人类叠氮化钠中毒病例的同行评议论文和新闻文章。最终回顾54篇文献、156例病例,年均报告7.8例,为1927至1999年综述报告率的三倍;中毒最常见于实验室工作人员、医务人员二次暴露或安全气囊破裂。低血压常见,部分需血管加压药,1例使用主动脉内球囊反搏;口服摄入者使用洗胃和/或活性炭,重症患者使用亚硝酸钠、硫代硫酸钠和/或羟钴胺。作者认为系统性中毒需积极血流动力学支持,基于机制考虑羟钴胺是治疗叠氮化钠中毒的合理选择。

要点

  • 2000至2020年共回顾54篇文献、156例叠氮化钠中毒病例,年均报告7.8例,为1927至1999年综述报告率的三倍。
  • 中毒最常见于实验室工作人员、医务人员二次暴露或安全气囊破裂。
  • 低血压常见,部分病例需血管加压药,1例患者接受主动脉内球囊反搏。
  • 口服叠氮化物摄入使用洗胃和/或活性炭,重症患者使用亚硝酸钠、硫代硫酸钠和/或羟钴胺。
  • 作者基于机制考虑认为羟钴胺是治疗叠氮化钠中毒的合理选择。

适用人群与场景

  • 实验室工作人员。
  • 发生二次暴露的医务人员。
  • 安全气囊破裂相关暴露者。
  • 口服摄入叠氮化钠的患者。

处置流程与药物剂量

  • 口服叠氮化物摄入:使用洗胃和/或活性炭。
  • 重症中毒患者:使用亚硝酸钠、硫代硫酸钠和/或羟钴胺。
  • 系统性中毒伴严重低血压:可能需要积极血流动力学支持,部分病例需血管加压药,1例患者接受主动脉内球囊反搏。
  • 作者基于机制考虑认为羟钴胺是治疗叠氮化钠中毒的合理选择。

红旗征与不能漏的情况

  • 低血压常见,部分病例需血管加压药,1例患者接受主动脉内球囊反搏。

研究设计与关键结果

  • 叙述性综述检索医学与报纸数据库,时间范围为2000年1月1日至2020年12月31日,检索词为「sodium azide」或「hydrazoic acid」与暴露和结局相关术语配对。
  • 共识别663篇同行评议论文和303篇报纸文章,去除重复和不合格来源后,回顾54篇文献,描述156例病例,年均报告7.8例。
  • 该报告率是先前覆盖1927至1999年综述报告率的三倍。
  • 中毒最常见于实验室工作人员、医务人员二次暴露或安全气囊破裂。
  • 低血压常见,部分病例需血管加压药,1例患者接受主动脉内球囊反搏。
  • 口服叠氮化物摄入使用洗胃和/或活性炭,重症患者使用亚硝酸钠、硫代硫酸钠和/或羟钴胺。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,叠氮化钠系统性中毒可能需要积极的血流动力学支持以应对严重低血压。
  • 作者基于机制考虑认为,羟钴胺是治疗叠氮化钠中毒的合理选择。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: Sodium azide is a highly toxic chemical. Its production has increased dramatically over the last 30 years due to its widespread use in vehicular airbags, and it is available for purchase online. Thus, accidental exposure to azide or use as a homicidal or suicidal agent could be on the rise, and secondary exposure to medical personnel can occur. No antidote exists for azide poisoning. We conducted a systematic review of azide poisoning to assess recent poisoning reports, exposure scenarios, clinical presentations, and treatment strategies.

METHODS: We searched both medical and newspaper databases to review the literature between 01/01/2000 and 12/31/2020, pairing the controlled vocabulary and keyword terms "sodium azide" or "hydrazoic acid" with terms relating to exposures and outcomes, such as "ingestion," "inhalation," "exposure," "poisoning," and "death." We included all peer-reviewed papers and news articles describing human azide poisoning cases from English and non-English publications that could be identified using English keywords. Data abstracted included the number, age, and gender of cases, mode of exposure, exposure setting, azide dose and route of exposure, symptoms, outcome, and treatment modalities.

RESULTS: We identified 663 peer-reviewed papers and 303 newspaper articles. After removing duplicated and non-qualifying sources, 54 publications were reviewed describing 156 cases, yielding an average of 7.8 reported azide poisoning cases per year. This rate is three times higher than in a previous review covering the period of 1927 to 1999. Poisoning occurred most commonly in laboratory workers, during secondary exposure of medical personnel, or from a ripped airbag. Hypotension occurred commonly, in some cases requiring vasopressors and one patient received an intra-aortic ballon pump. Gastric lavage and/or activated charcoal were used for oral azide ingestion, and sodium nitrite, sodium thiosulfate, and/or hydroxocobalamin were used in severely poisoned patients.

CONCLUSIONS: Recent increases in azide poisoning reports may stem from greater commercial use and availability. Treatment of systemic poisoning may require aggressive hemodynamic support due to profound hypotension. Based on mechanistic considerations, hydroxocobalamin is a rational choice for treating azide poisoning.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Tat J, Heskett K, Satomi S, et al. Sodium azide poisoning: a narrative review. Clin Toxicol (Phila). 2021. PMID: 34128439. doi:10.1080/15563650.2021.1906888

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。